STAMFORD, Conn., Aug. 28, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced ...
GOMEKLI™ (mirdametinib) capsules and tablets for oral suspension · GlobeNewswire Inc. STAMFORD, Conn., Feb. 11, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a ...
Presented positive topline data from the pivotal Phase 2b ReNeu trial evaluating mirdametinib, an investigational oral MEK inhibitor, in pediatric and adult patients with neurofibromatosis type ...
Desmoid tumors, though benign, are locally aggressive with tendril-like growths causing pain, limited range of motion and even impaired mobility. (SpringWorks) SpringWorks Therapeutics is launching a ...
SpringWorks Therapeutics, Inc. SWTX expanded its existing clinical collaboration agreement with GSK GSK. The partnership is evaluating the combination of SpringWorks’ investigational oral gamma ...
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.76% By Investing.com - May 27, 2022 Investing.com – U.S. stocks were higher after the close on Friday, as gains in the ...
FDA approved SpringWorks' mirdametinib for NF1 patients with symptomatic plexiform neurofibromas, granting a priority review voucher. In the Phase 2b trial, Gomekli showed a 41% ORR in adults and 52% ...
Nov 28 (Reuters) - SpringWorks Therapeutics' (SWTX.O), opens new tab drug for treating adult patients with a type of rare non-cancerous soft-tissue tumor will be sold in the U.S. at a list price of ...
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. & SAN MATEO, Calif. & STAMFORD, Conn.--(BUSINESS WIRE)--MapKure, LLC, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE ...
NEW YORK--(BUSINESS WIRE)--SpringWorks Therapeutics, a mission-driven medicines company dedicated to developing innovative potential new treatments for underserved patient communities, announced its ...
“SpringWorks is committed to developing genomically-targeted therapies for patients with cancer and our MAPK directed portfolio is a cornerstone of our efforts. In particular, we are encouraged by the ...
– Approval based on positive data from Phase 2b ReNeu trial, which showed GOMEKLI treatment resulted in robust ORR, deep and durable reductions in tumor volume, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results